<DOC>
	<DOCNO>NCT01126112</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety first-line single-agent panitumumab frail elderly patient advance Wild Type K-RAS colorectal cancer</brief_summary>
	<brief_title>Study First-line Single-agent Panitumumab Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety first-line single-agent panitumumab frail elderly patient advance Wild Type K-RAS colorectal cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Inform Consent Age &gt; 70 year . Histologically document metastatic colorectal cancer candidate surgical resection Wild type KRAS Measurable disease RECIST Criteria Intermediate Highrisk group accord Köhne Prognostic Classification ECOG status &lt; 3 Magnesium ≥ institutional low limit normal frail elderly patient candidate chemotherapy : Frail elderly patient : Presence one follow criterion : Dependence one basic daily living activity ( Katz Index ) Three comorbid condition accord Charlson scale dependence one instrumental activity daily live ( IADL ) Presence one follow geriatric syndrome ( age &gt; 85 year , fecal urinary incontinence absence stress , frequent fall , spontaneous bone fracture , neglect ) Presence one follow criterion make patient candidate chemotherapy : neutrophil &lt; 2000/mm3 platelet &lt; 100.000/mm3 creatinine clearance &lt; 30 ml/min bilirubin level &gt; 1.5 x ULN creatinine clearance &lt; 30 ml/min AST ALT level &gt; 3 x UNL ( liver metastasis &gt; 5 x ULN ) Patients exclude study receive prior systemic therapy treatment metastatic colorectal carcinoma antiEGFR therapy , exception adjuvant fluoropyrimidinebased chemotherapy give least six month prior enrolment oxaliplatin least 12 month prior enrolment . Systemic chemotherapy , hormonal therapy , immunotherapy experimental approve proteins/antibodies ( eg , bevacizumab ) ≤ 30 day inclusion Unresolved toxicities prior systemic therapy , opinion investigator , qualify patient inclusion Patients cognitively impair severe depression accord mini mental state examination geriatric depression scale . Patients central nervous system metastasis , significant cardiovascular disease , also exclude . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest CT scan Treatment systemic infection within 14 day initiate study treatment Radiotherapy &lt; 14 day prior inclusion study . Active inflammatory bowel disease bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) History medical condition may increase risk associate study participation may interfere interpretation study result Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection subject allergic ingredient study medication Staphylococcus protein A Any comorbid disease would increase risk toxicity Any investigational agent within 30 day enrolment Must major surgical procedure within 28 day enrolment Subject unwilling unable comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>advanced colorectal cancer ; K-RAS ; panitumumab</keyword>
	<keyword>advanced Wild Type K-RAS colorectal cancer</keyword>
</DOC>